Multiple Sclerosis, Relapsing-Remitting  >>  GSK2618960  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK2618960 / GSK
NCT01808482: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Terminated
1
16
Europe
Part A: 100 mg/mL GSK2618960, Part A: matching placebo, Part B: Dose of GSK2618960 decided from Part A, Part B: matching placebo, Part C: Dose of GSK2618960 decided from Part A and B
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
08/13
08/13

Download Options